PortfoliosLab logoPortfoliosLab logo
GNOM.L vs. BTEK.L
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

GNOM.L vs. BTEK.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Global X Genomics & Biotechnology UCITS ETF (GNOM.L) and iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Different Trading Currencies

GNOM.L is traded in USD, while BTEK.L is traded in GBP. To make them comparable, the BTEK.L values have been converted to USD using the latest available exchange rates.

Returns By Period

In the year-to-date period, GNOM.L achieves a 22.10% return, which is significantly higher than BTEK.L's 15.09% return.


GNOM.L

1D
-0.17%
1M
11.69%
6M
15.71%
YTD
22.10%
1Y
62.79%
3Y*
4.58%
5Y*
10Y*

BTEK.L

1D
1.00%
1M
9.60%
6M
13.21%
YTD
15.09%
1Y
50.03%
3Y*
17.58%
5Y*
5.91%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

GNOM.L vs. BTEK.L - Yearly Performance Comparison


2026 (YTD)20252024202320222021
GNOM.L
Global X Genomics & Biotechnology UCITS ETF
22.10%19.30%-17.99%-5.77%-37.21%-8.59%
BTEK.L
iShares Nasdaq US Biotechnology UCITS ETF
15.09%32.98%-1.86%5.59%-12.08%-5.16%

Correlation

The correlation between GNOM.L and BTEK.L is 0.80, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.80

Correlation (3Y)
Calculated over the trailing 3-year period

0.79

Correlation (All Time)
Calculated using the full available price history since Nov 2, 2021

0.80

The correlation between GNOM.L and BTEK.L has been stable across timeframes, ranging from 0.79 to 0.80 - a consistent structural relationship.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GNOM.L vs. BTEK.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNOM.L
GNOM.L Risk / Return Rank: 7777
Overall Rank
GNOM.L Sharpe Ratio Rank: 8383
Sharpe Ratio Rank
GNOM.L Sortino Ratio Rank: 8383
Sortino Ratio Rank
GNOM.L Omega Ratio Rank: 7373
Omega Ratio Rank
GNOM.L Calmar Ratio Rank: 8080
Calmar Ratio Rank
GNOM.L Martin Ratio Rank: 6464
Martin Ratio Rank

BTEK.L
BTEK.L Risk / Return Rank: 9191
Overall Rank
BTEK.L Sharpe Ratio Rank: 9191
Sharpe Ratio Rank
BTEK.L Sortino Ratio Rank: 8989
Sortino Ratio Rank
BTEK.L Omega Ratio Rank: 8484
Omega Ratio Rank
BTEK.L Calmar Ratio Rank: 9696
Calmar Ratio Rank
BTEK.L Martin Ratio Rank: 9393
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNOM.L vs. BTEK.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology UCITS ETF (GNOM.L) and iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


GNOM.LBTEK.LDifference
Sharpe ratioReturn per unit of total volatility

-0.36

Sortino ratioReturn per unit of downside risk

-0.44

Omega ratioGain probability vs. loss probability

1.34

1.40

-0.06

Calmar ratioReturn relative to maximum drawdown

3.35

6.38

-3.03

Martin ratioReturn relative to average drawdown

9.16

18.62

-9.46

GNOM.L vs. BTEK.L - Sharpe Ratio Comparison

The current GNOM.L Sharpe Ratio is 2.12, which is comparable to the BTEK.L Sharpe Ratio of 2.48. The chart below compares the historical Sharpe Ratios of GNOM.L and BTEK.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

GNOM.L vs. BTEK.L - Drawdown Comparison

The maximum GNOM.L drawdown since its inception was -69.32%, which is greater than BTEK.L's maximum drawdown of -38.25%. Use the drawdown chart below to compare losses from any high point for GNOM.L and BTEK.L.


Loading charts...

Drawdown Indicators


GNOM.LBTEK.LDifference

Max Drawdown

Largest peak-to-trough decline

-69.32%

-38.25%

-31.07%

Max Drawdown (1Y)

Largest decline over 1 year

-18.91%

-7.81%

-11.10%

Max Drawdown (3Y)

Largest decline over 3 years

-44.77%

-26.89%

-17.88%

Max Drawdown (5Y)

Largest decline over 5 years

-38.25%

Current Drawdown

Current decline from peak

-37.11%

-4.00%

-33.11%

Average Drawdown

Average peak-to-trough decline

-47.16%

-18.08%

-29.08%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.92%

2.68%

+4.24%

Volatility

GNOM.L vs. BTEK.L - Volatility Comparison

Global X Genomics & Biotechnology UCITS ETF (GNOM.L) has a higher volatility of 8.41% compared to iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) at 5.94%. This indicates that GNOM.L's price experiences larger fluctuations and is considered to be riskier than BTEK.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GNOM.LBTEK.LDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.41%

5.94%

+2.47%

Volatility (6M)

Calculated over the trailing 6-month period

22.18%

15.62%

+6.56%

Volatility (1Y)

Calculated over the trailing 1-year period

29.87%

20.15%

+9.72%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

33.11%

24.78%

+8.33%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

33.11%

25.60%

+7.51%

GNOM.L vs. BTEK.L - Expense Ratio Comparison

GNOM.L has a 0.50% expense ratio, which is higher than BTEK.L's 0.35% expense ratio.


Dividends

GNOM.L vs. BTEK.L - Dividend Comparison

Neither GNOM.L nor BTEK.L has paid dividends to shareholders.


Tickers have no history of dividend payments

Frequently Asked Questions


GNOM.L and BTEK.L have a correlation of 0.80, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

On fees, BTEK.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

BTEK.L is cheaper with a 0.35% expense ratio, compared with 0.50% for GNOM.L.

GNOM.L tracks Global X Genomics & Biotechnology UCITS ETF, while BTEK.L tracks NASDAQ Biotechnology TR USD. They also come from different issuers: Global X and iShares. Their fees differ too: 0.50% for GNOM.L and 0.35% for BTEK.L.

Portfolio Optimizer

Find the right allocation for GNOM.L and BTEK.L

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer